MDPI Contact

MDPI
St. Alban-Anlage 66,
4052 Basel, Switzerland
Support contact
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18

For more contact information, see here.

秒速赛车开奖直播:Advanced Search

You can use * to search for partial matches.

Search Results

1 article matched your search query. Search Parameters:
Authors = Eliscer Guzman

秒速赛车是哪里的开奖 www.0dv0k.cn Matches by word:

ELISCER (1) , GUZMAN (190)

View options
order results:
result details:
results per page:
Articles per page View Sort by
Displaying article 1-50 on page 1 of 1.
Export citation of selected articles as:
Open AccessReview Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
Received: 29 June 2018 / Revised: 11 July 2018 / Accepted: 11 July 2018 / Published: 13 July 2018
PDF Full-text (566 KB) | HTML Full-text | XML Full-text
Abstract
The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic
  • 天生三条腿 半岁牛犊活成“牛坚强” 2019-02-20
  • 晋中市直机关将开展纪念建党97周年“红色+”系列活动 2019-02-20
  • 吴燕生任中国航天科技集团有限公司董事长 2019-02-20
  • 美国一大学将接受中国高考成绩 美媒:中国学子多了一条路 2019-02-19
  • 台媒曝吴建豪离婚 百亿身家娇妻收两封离婚协议书 2019-02-19
  • 娄勤俭确保江苏"四好农村路"建设走在全国前列 2019-02-18
  • 传媒每周热闻第360期:全国党报网站总编辑贺新春 央视春晚主持阵容曝光 2019-02-18
  • 13少年被逼参与盗窃遭烟头烫伤 21天撬130辆车 2019-02-18
  • 反思“天价账单”要看共性问题 2019-02-18
  • 西部网(陕西新闻网)www.cnwest.com 2019-02-17
  • 权健边路尖刀加盟初期曾被质疑 如今获球迷点赞 2019-02-17
  • 脱下警服当支书 老高回村以后(新时代·面孔) 2019-02-17
  • 党员干部注意了!这些事情不能做 2019-02-16
  • 甘肃裕河:“美猴王”下山 2019-02-16
  • China Fokus Richtungsweisende Zwei Tagungen stellen Weichen für neue ra“ 2019-02-15
  • 296| 261| 195| 844| 959| 746| 622| 548| 577| 929| [...] Read more.
    The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal antibodies directed against PCSK9, given on a background of statin therapy, have been shown to markedly decrease LDL-C levels and significantly reduce cardiovascular risk. The small interfering RNA (siRNA) molecules have been used recently to target the hepatic production of PCSK9. siRNA interferes with the expression of specific genes with complementary nucleotide sequences by affecting the degradation of mRNA post-transcription, thus preventing translation. Inclisiran is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. This review aims to present and discuss the current clinical and scientific evidence pertaining to inclisiran, which is a new promising agent in the management of hypercholesterolemia. Full article
    Figures

    Figure 1

    Figure 1
    <p>Mechanism of action of inclisiran in conjunction with the action of PCSK9.</p>
    Full article ">

    Years

    Subjects

    Refine Subjects

    Journals

    Refine Journals

    Article Types

    Refine Types

    Countries / Territories

    Refine Countries / Territories
    秒速赛车是哪里的开奖
    Back to Top